An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Depression

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

288 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-04-30

Study Completion Date

2007-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate the efficacy and safety of SR58611A in elderly patients with depression.The primary objective is to evaluate the efficacy of a 700 mg dose of SR58611A compared to placebo in elderly patients with depression. The secondary objectives are to evaluate the safety of SR58611A and to evaluate the efficacy of SR58611A on disability and quality of life in elderly patients with depression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice Daily) of SSR149415 in Patients With Major Depressive Disorder

NCT00361491

Depressive Disorder

COMPLETED PHASE2

Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine

NCT00825058

Major Depressive Disorders

COMPLETED PHASE3

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)

NCT00385307

Major Depressive Disorder

COMPLETED PHASE3

A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder

NCT03000530

Major Depression

COMPLETED PHASE2

A Safety, Efficacy and Tolerability Study of SEP-225289

NCT00584974

Depressive Disorder, Major

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SR58611A

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Outpatients or inpatients
* Major Depressive Disorder (MDD) with a recurrent Major Depressive Episode (MDE) according to DSM IV-TR criteria.
* MADRS score equal of above 22.

Exclusion Criteria

* Patients with a current significant risk of suicide in the investigator's clinical judgment.
* The duration of the current depressive episode is greater than 2 years.
* Patients whose current depressive episode is secondary to a general medical condition
* Patients with a lifetime history according to MINI at screening of:bipolar disorder, psychotic disorder, antisocial personality disorder.
* Patients with a current history according to MINI at screening of anxiety disorders, alcohol dependence or abuse or substance dependence or abuse
* Patients with severe or unstable concomitant medical conditions.
* History of seizures other than a single childhood febrile seizure.
* Patients with abnormal thyroid functioning.
* Patients with clinically significant ECG findings at screening.
* Patients who have taken an investigational drug in the last 3 months prior to screening.
* Any subject who has previously participated in a SR58611A protocol.
* Patients with Mini-Mental State Examination (MMSE) score \< 25 at screening.

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No